Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05830318
Other study ID # 0901
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 23, 2023
Est. completion date January 31, 2024

Study information

Verified date July 2023
Source University of Leicester
Contact Andre Ng
Phone 0116 2502438
Email andre.ng@leicester.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Assess the usability and acceptance of the P-STEP app, through allowing participants with specific chronic conditions to pilot the app for 12-weeks.


Description:

Participants are asked to use mobile app for 12 weeks & complete baseline, 6 week and 12 week assessments.


Recruitment information / eligibility

Status Recruiting
Enrollment 380
Est. completion date January 31, 2024
Est. primary completion date December 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Adult = 18 years - Live within the boundaries of the test site (Leicester, UK). - Diagnosed with one (or more) of the following conditions: asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), coronary heart disease (CHD), heart failure (HF), type 2 diabetes - Android smartphone which has access to the internet - Can walk outside for a minimum of 5 minutes without feeling uneasy/unsteady - Available to pilot the app for 12 weeks from August-December 2023 - Able to give informed consent to participate in the evaluation Exclusion Criteria: - English language restriction - Advised not to do exercise by a health care professional, in the last 12 months. - Access to an iOS smartphone only - Diagnosed with dementia, learning disability, mental health disorders (other than depression or anxiety), epilepsy - Receiving palliative care - Pregnant - Chest pain at rest - Unsteady when standing or walking - Current cancer patient - Part of the P-STEP User Engagement group

Study Design


Intervention

Other:
P-STEP Mobile Application
A mobile application that allows you track your walking habits while keeping you up to date with air quality information.

Locations

Country Name City State
United Kingdom University of Leicester Leicester

Sponsors (1)

Lead Sponsor Collaborator
University of Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary System Usability Scale the System Usability Scale (SUS) at 12 weeks. The SUS a validated scale and a popular instrument for assessing perceived usability. There are 10 items in total, 5 with a positive tone and 5 with a negative tone, the response of each ranging from strongly disagree to strongly agree. The participant's scores will be transformed onto a 0-100 scale. General guidance suggests a SUS score 68 and above to be considered above average and below 68 is below average. Scores range from 0-100, a higher score indicates higher usability. 12 weeks
Secondary Usability of P-STEP app Other than the SUS, 9 usability questions relating to the specific features of the app will be asked. Participants will also be asked to provide their general feedback on the app as well as how much they used it. Individual items in the questionnaire will be summarised with percentages. Scores range from 1-5, a higher score indicates higher usability. 12 weeks
Secondary User Engagement Scale Short Form The User Engagement Scale - Short Form (UES-SF) is a reliable a valid questionnaire containing twelve items that measure user engagement categorised into; focused attention, perceived usability, aesthetic appeal, and reward. These categories can be calculated to get an average of the scores. An overall user engagement score can be calculated with UES-SF by adding together all 12 items and dividing them equally. Scores are presented on a scale 1-5. The items can be averaged into 4 categories or averaged for an overall score. Scores range from 0-60, a higher score indicates higher user engagement. 12 weeks
Secondary SF-12 Health Questionnaire The short form 12 item (SF-12v2) health survey measures functional health and well-being from the participant's perspective. It assesses eight domains; physical functioning, physical role, pain, general health, vitality, social functioning, social role, mental health. Each domain contributes to two summary scores; physical component summary (PCS) and mental component summary (MCS). SF-12v2 responses will be scored and interpreted using the SF-12v2 user guide. The 8 domains will generate two summary scores; physical component score (PCS) and mental component score (MCS). Scores for the PCS and MCS range from 0-100, a higher score indicates a higher quality of life. 12 weeks
Secondary Recent Physical Activity Questionnaire The RPAQ is designed to find out about a participant's physical activity in their everyday life. The RPAQ will be scored and interpreted using the scoring guidelines published by the Authors. All activities are categorised with respect to their intensity, on a scale of sedentary (<1.5), light (1.5-<3), moderate (3-6) and vigorous (>6). Each activity is scored by hours a day multiplied by the intensity of the activity. A higher RPAQ score indicates higher levels of physical activity. 12 weeks
Secondary Feasibility outcome - Interest Percentage of those potentially eligible who register their interest. 2 months
Secondary Feasibility outcome - Enrolment Percentage of participants that register interest enrol on the study. 2 months
Secondary Feasibility outcome - App administration Percentage that successfully download the app. 3 months
Secondary Feasibility outcome - App acceptability Percentage of participants who enrol and complete the 12-week study 3 months
Secondary Feasibility outcome - Acceptability of the outcome measures Completion levels of questionnaire 3 months
Secondary All cause mortality Description of all cause mortality at 3 months 3 months
Secondary Cardiovascular events Description of cardiovascular events at 3 months 3 months
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device